CIA
RLAY icon

Capital Impact Advisors’s Relay Therapeutics RLAY Stock Holding History

Capital Impact Advisors’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-24,117
Closed -$203K – 115
2023
Q3 		$203K Hold
24,117
– – 0.34% 97
2023
Q2 		$303K Buy
24,117
+1,505
+7% +$18.7K 0.33% 138
2023
Q1 		$372K Buy
22,612
+6,184
+38% +$111K 0.46% 104
2022
Q4 		$245K Buy
16,428
+1,125
+7% +$21.5K 0.24% 169
2022
Q3 		$275K Buy
15,303
+2,464
+19% +$54.1K 0.27% 153
2022
Q2 		$215K Buy
+12,839
New +$275K 0.2% 191

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Capital Impact Advisors's RLAY Position: Q4 2023 in Review

Capital Impact Advisors sold out of Relay Therapeutics (RLAY) in Q4 2023, closing a stake of 24,117 shares — an estimated $203K sold.

Capital Impact Advisors first reported a position in RLAY in Q2 2022 and held it in 6 quarters. The position peaked at $372K in Q1 2023. 177 funds tracked by Wall St. Rank hold RLAY as of Q4 2023.

  • Capital Impact Advisors reported no remaining Relay Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Capital Impact Advisors sold 24,117 Relay Therapeutics shares in Q4 2023, an estimated $203K.
  • Capital Impact Advisors first reported a position in Relay Therapeutics in Q2 2022 and held it in 6 quarters.
  • Capital Impact Advisors's Relay Therapeutics position peaked at $372K in Q1 2023.
  • 177 funds tracked by Wall St. Rank held Relay Therapeutics as of Q4 2023.

Based on Capital Impact Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.